End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
780.8 INR | +2.03% | -1.41% | +13.77% |
May. 30 | India's Apollo Hospitals misses Q4 profit estimates on higher expenses | RE |
May. 24 | Jefferies Adjusts Max Healthcare’s Price Target to INR940 From INR915, Keeps at Buy | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 58.05 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.77% | 9.11B | - | ||
+22.65% | 86.96B | C+ | ||
-23.68% | 75.65B | B- | ||
+0.49% | 26.97B | C+ | ||
+6.91% | 17.89B | A- | ||
-13.47% | 16.58B | B | ||
+2.68% | 15.73B | A- | ||
+69.13% | 13.01B | C- | ||
+74.99% | 12.92B | C+ | ||
+36.80% | 12.57B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MAXHEALTH Stock
- MAXHEALTH Stock
- Ratings Max Healthcare Institute Limited